Germline POLE and POLD1 proofreading domain mutations in endometrial carcinoma from Middle Eastern region

Table 4 Association of clinico-pathological characteristics with POLD1 protein expression in Endometrial cancer

	Total		Low		High		p value
	No.	%	No.	%	No.	%	p value
No. of patients	419		251	59.9	168	40.1
Age (years)
≤ 50	78	18.6	47	60.3	31	39.7	0.9439
> 50	341	81.4	204	59.8	137	40.2
Histologic subtype
Type I	359	88.2	221	61.6	138	38.4	0.0728
Type II	48	11.8	23	47.9	25	52.1
Lymphovascular invasion
Present	90	27.7	51	56.7	39	43.3	0.4923
Absent	235	72.3	143	60.8	92	39.2
Grade
Grade 1	140	34.4	101	72.1	39	27.9	0.0024
Grade 2	140	34.4	77	55.0	63	45.0
Grade 3	127	31.2	69	54.3	58	45.7
pT
T1	290	69.4	183	63.1	107	36.9	0.2590
T2	54	12.9	27	50.0	27	50.0
T3	56	13.4	31	55.4	25	44.6
T4	18	4.3	10	55.6	8	44.4
pN
N0	389	92.8	235	60.4	154	39.6	0.4491
N1–N2	30	7.2	16	53.3	14	46.7
pM
M0	396	94.7	240	60.6	156	39.4	0.3276
M1	22	5.3	11	50.0	11	50.0
Stage
I	268	64.1	171	63.8	97	36.2	0.1772
II	47	11.2	23	48.9	24	51.1
III	68	16.3	38	55.9	30	44.1
IV	35	8.4	19	54.3	16	45.7
Microsatellite status
MSI	52	12.4	34	65.4	18	34.6	0.3854
MSS	367	87.6	217	59.1	150	40.9
POLD1 mutation
Present	2	0.5	1	50.0	1	50.0	0.7767
Absent	417	99.5	250	59.9	167	40.1
5 year overall survival				90.3		81.3	0.0555

ISSN: 1475-2867